Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cryogesic Spray is a fast-acting topical vapo-coolant containing chloroethane (ethyl chloride) as its active ingredient. It functions as a cryoanalgesic by rapidly evaporating upon application to the skin, which induces immediate cooling and desensitizes peripheral sensory nerve endings. This process produces a transient local analgesic effect lasting approximately 30–45 seconds. It is primarily indicated for the prevention of pain associated with injections and minor invasive procedures, such as arterial puncture, as well as for the temporary relief of minor sports injuries (sprains, strains, bruises) and deep muscle pain when used in conjunction with stretching techniques. The product is manufactured by Acorus Therapeutics and has been evaluated in clinical settings, including emergency department trials comparing its efficacy against injectable anesthetics like lignocaine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloroethane.